-+ 0.00%
-+ 0.00%
-+ 0.00%

DroneShield Stock And Other Financially Fit Penny Stocks Worth Watching

Simply Wall St·07/14/2026 07:25:38
语音播报

With oil shocks, higher global yields and mixed inflation signals shaping markets, many investors are looking for ways to stay exposed to growth potential while still paying close attention to balance sheet strength. That is where the Financially Fit Penny Stocks screener comes in, focusing on companies trading below 5 that also clear a basic financial health bar. For readers who want to explore up and coming stocks without ignoring risk, this article highlights three of the strongest candidates from the screener that stand out on financial quality and may deserve a spot on a watchlist.

DroneShield (ASX:DRO)

Overview: DroneShield is a Sydney based defence technology company that builds hardware and software to detect and neutralise hostile drones for military, security and critical infrastructure customers globally, from airports and stadiums to data centres and gas pipelines. Its product range spans command and control platforms, wearable detectors and handheld jamming devices that help customers manage drone threats in real time.

Operations: DroneShield currently generates all of its A$216.8 million in revenue from the Aerospace & Defense segment, with sales primarily across Australia and the rest of the world at A$195.0 million and the USA at A$29.7 million.

Market Cap: A$2.10b

DroneShield sits at the centre of a fast developing counter drone market, with the business shifting from one off gadget sales to repeat procurement from defence and security agencies. The company has recently turned profitable and analysts expect earnings to grow, supported by forecasts of revenue expansion and a pipeline of institutional contracts. At the same time, a relatively high P/S ratio and low current ROE point to execution risk if margins and contract visibility do not keep improving. Reliance on external borrowing and an ASIC inquiry add further complexity. Growing roles in projects like the Kansas City World Cup 2026 deployment may be relevant for understanding what is driving demand and how durable it could be.

DroneShield’s shift to recurring defence contracts and recent move into profitability can look like a straightforward growth story, but the real tension lies in its valuation and borrowing. Get the full picture in the DCF valuation analysis for DroneShield

DRO Discounted Cash Flow as at Jul 2026
DRO Discounted Cash Flow as at Jul 2026

Sigma Healthcare (ASX:SIG)

Overview: Sigma Healthcare is an Australian pharmacy group that franchises and supports retail pharmacies, distributes medicines and health products nationwide, and provides logistics and health services under brands such as Chemist Warehouse, Amcal and Discount Drug Stores, including online channels.

Operations: Sigma Healthcare generates A$9.55b in revenue from its Healthcare segment, with A$9.16b from Australia and A$389.8m from international markets.

Market Cap: A$33.59b

Sigma Healthcare gives you exposure to Australia’s pharmacy and medicines supply chain at scale, with a single Healthcare segment generating almost A$9.55b in revenue. The company has a rich history and recently walked away from a potential A$10b Boots acquisition, signalling discipline around capital and focus on its home market while still keeping the door open to future overseas options. At the same time, a high P/E, contracting profit margins and reliance on external borrowing put pressure on execution, especially with a relatively new and less experienced board. How that trade off between growth ambitions, funding risk and governance quality plays out is where the real investment debate on Sigma Healthcare starts.

Sigma Healthcare’s stalled margins and rich P/E might be masking a sharper story around growth ambitions and funding risk, and the real twist sits inside the analysis report for Sigma Healthcare

SIG Discounted Cash Flow as at Jul 2026
SIG Discounted Cash Flow as at Jul 2026

Stanmore Resources (ASX:SMR)

Overview: Stanmore Resources is a Brisbane based miner focused on exploring, developing, producing and selling metallurgical coal across a large tenement portfolio in Queensland’s Bowen and Surat basins, supplying coal that is used primarily in steelmaking. The company was founded in 2008, rebranded from Stanmore Coal in 2021, and now operates as a subsidiary of Golden Investments (Australia) Pte. Ltd.

Operations: Stanmore Resources generates all of its A$1.88b in revenue from producing and selling metallurgical and thermal coal, with customers mainly in Asia (A$1.19b), Europe (A$495.4m) and South America (A$198.8m).

Market Cap: A$2.22b

Stanmore Resources stands out in the Financially Fit Penny Stocks screener because it combines a coal portfolio geared to steelmaking demand with a balance sheet and valuation that still reflect past losses and volatility. Forecasts in the market point to earnings moving from a loss to A$109.4 million by 2029, with some analysts citing cost efficiencies, automation and brownfield projects as potential supports for long term production. Current pricing has also been interpreted by some as leaving the stock trading below certain fair value estimates and analyst targets. At the same time, heavy reliance on metallurgical coal, Queensland weather risks, tighter project approvals and potential funding needs for a possible Anglo American asset deal mean any investment thesis needs to weigh potential upside against concentrated operational and regulatory risk that may not be fully captured by headline forecasts.

Stanmore Resources sits where earnings recovery, past losses and coal concentration intersect, and the full story is not always clear from headlines alone. It is therefore worth reading the 4 key rewards and 1 important warning sign

SMR Discounted Cash Flow as at Jul 2026
SMR Discounted Cash Flow as at Jul 2026

The three stocks covered here are only a small sample of what shows up when you run the full Financially Fit Penny Stocks screener, which currently flags 402 more companies whose financial profiles and stories may be just as compelling. Use Simply Wall St to identify, filter and analyze the specific catalysts and narratives that matter to you, so you can focus on the highest conviction opportunities that fit your own approach.

Take Control of Your Investment Journey

If Sigma Healthcare or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others?

New ideas can move from quiet to flying under momentum quickly, and early research often ages fast. Scan fresh stock sets before the crowd catches on to position yourself earlier in the process.

  • Spot potential income ideas by reviewing companies in the 6 dividend fortresses while yields still look compelling and pricing has not fully adjusted.
  • Track companies that support AI capacity by checking infrastructure stocks in the 52 AI infrastructure stocks before momentum traders start to pay closer attention.
  • Explore possible materials themes by scanning producers in the 8 top copper producer stocks while many investors are still focused elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.